Patent: 11,046,750
✉ Email this page to a colleague
Summary for Patent: 11,046,750
| Title: | Factor VIII proteins having ancestral sequences, expression vectors, and uses related thereto |
| Abstract: | This disclosure relates to recombinant or chimeric FVIII proteins, variants, and vectors encoding the proteins containing one or more ancestral mutations. In certain embodiments, one or more protein domains comprise amino acid sequences that are derived from ancestrally reconstructed amino acid sequences. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising the proteins or vectors and related methods of inducing blood clotting. |
| Inventor(s): | H. Trent Spencer, Christopher B. Doering, Philip M. Zakas, Eric Gaucher |
| Assignee: | Emory University , Georgia Tech Research Corp |
| Application Number: | US16/874,121 |
| Patent Claims: | see list of patent claims |
Details for Patent 11,046,750
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Valeant Pharmaceuticals Luxembourg S.à.r.l. | SILIQ | brodalumab | Injection | 761032 | February 15, 2017 | ⤷ Start Trial | 2040-05-14 |
| Bausch Health Ireland, Limited | SILIQ | brodalumab | Injection | 761032 | 15-Feb-17 | ⤷ Start Trial | 2040-05-14 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 11,046,750
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2016123200 | ⤷ Start Trial |
| United States of America | 2021388055 | ⤷ Start Trial |
| United States of America | 2020277356 | ⤷ Start Trial |
| United States of America | 2018009873 | ⤷ Start Trial |
| United States of America | 11897938 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
